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Introduction. Mesenchymal stromal cells (MSC) have immunomodulatory features. The aim of this study was to investigate the
migration and homing potential of endogenous circulating MSC in virus negative inflammatory cardiomyopathy (CMi).Methods.
In 29 patients with (𝑛 = 23) or without (𝑛 = 6) CMi undergoing endomyocardial biopsies (EMB), transcardiac gradients (TCGs)
of circulating MSC were measured by flow cytometry from blood simultaneously sampled from aorta and coronary sinus. The
presence of MSC in EMB, cardiac inflammation, and SDF-1𝛼 mRNA expression were detected via immunohistochemistry and
real-time PCR. Results. MSC defined as CD45−CD34−CD11b−CD73+CD90+ cells accounted for 0.010 [0.0025–0.048]%/peripheral
mononuclear cell (PMNC) and as CD45−CD34−CD11b−CD73+CD105+ cells for 0.019 [0.0026–0.067]%/PMNC, both with similar
counts in patients with or without cardiac inflammation. There was a 29.9% (𝑃 < 0.01) transcardiac reduction of circulating MSC
in patients with CMi, correlating with the extent of cardiac inflammation (𝑃 < 0.05, multivariate analysis). A strong correlation was
found between the TCG of circulating MSC and numbers of MSC (CD45−CD34−CD90+CD105+) in EMB (𝑟 = −0.73, 𝑃 < 0.005).
SDF-1𝛼 was the strongest predictor for increased MSC in EMB (𝑃 < 0.005, multivariate analysis). Conclusions. Endogenous MSC
continuously migrate to the heart in patients with CMi triggered by cardiac inflammation.
1. Introduction
Despite advances in medical procedures, the prognosis of
inflammatory cardiomyopathy (CMi), a cause for dilated
cardiomyopathy, is poor [1]. The character of inflammatory
response is the pivotal parameter for the prognosis of patients
with CMi [2]. The delicate balance between protective and
deleterious immune mechanisms is a decisive factor in the
evolution of myocardial damage [3], of which the complex
mechanisms involved are not yet completely understood.
Beyond others, the innate immune system [4], cardiac
cytokines, autoantibodies, and probably also mesenchymal
stromal cells (MSC) [5] are involved in this process. MSC
are of special interest, since they produce growth factors and
cytokines [6] mediating endogenous activation of resident
cardiac stem cells [7] in a paracrine manner, and have
profound immunomodulatory features [8]. MSC mediate
their complex immunomodulatory effects by interacting with
cells from both the innate and adaptive immune system
resulting in skewing the immune response towards an anti-
inflammatory/tolerant phenotype [9]. They suppress T-cell
proliferation [10], modulate dendritic cell function into a reg-
ulatory phenotype, and alter their cytokine secretion profile
towards an upregulation of anti-inflammatory cytokines such
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as interleukin- (IL-) 10 and downregulation of inflamma-
tory cytokines [11]. MSC counteract tissue injury via their
capacity to promote endogenous tissue regeneration and via
immunomodulation after selective migration to the site of
injury, a process in which stromal derived factor- (SDF-) 1𝛼
is essential [12]. This feature supports the intravenous (i.v.)
administration of MSC as application route in CMi, whose
efficacy has been demonstrated in experimental studies of
acute myocarditis [8, 13]. At present, no clinical studies have
yet been performed treating patients with CMi by i.v. admin-
istration of MSC. Before starting clinical i.v. application of
MSC in patients with CMi, clarification in the potential of
MSC tomigrate and home to the heart in patients with CMi is
warranted. Homing is a complicated process orchestrated by
distinct chemokines. First, regenerating cells are recruited to
the site of damage; thereafter they adhere to the vessel wall or
migrate into the tissue.Thereafter, SDF-1𝛼 helps to retain cells
in the tissue.Therefore, the aimof this studywas to investigate
the migration and homing potential of endogenous circulat-
ing MSC in patients with virus negative CMi.
2. Methods
2.1. Patients and Control Subjects. Patients with clinical indi-
cation for an EMB were consecutively recruited between
November 2008 and June 2009 in our own centre. Inclusion
criteriawere age between 18 and 75 years. Indications for EMB
were reduced ejection fraction in the presence of a normal
coronary angiogram (𝑛 = 16), symptoms of heart failure
despite normal left ventricular ejection fraction (LVEF) (𝑛 =
7), LV hypertrophy (𝑛 = 2), or cardiac arrhythmias (𝑛 = 4).
We excluded patients with proof of virus genomes in EMB
of Human Herpes virus 6, Epstein Barr virus, Enterovirus,
Adenovirus, and Parvovirus B19, for the latter with genome
equivalence >500/𝜇g. In addition, exclusion criteria were
coronary heart disease, antiviral, immunomodulatory, or
immunosuppressive therapy within the last 6 months, acute
myocarditis, clinical or biochemical evidence of the presence
of concomitant chronic inflammatory disease, chronic renal
insufficiency (creatinine ≥ 1.4mmol/L), inability to under-
stand the consent form, participation in or consent to par-
ticipate in another study, or malignant disease. All study par-
ticipants gave their written informed consent, and the study
was approved by the ethics committee of the Charite´, Berlin.
Physical examinations, clinical assessments including
echocardiography and ECG, as well as laboratory controls
were analysed prospectively. The assessment of clinical com-
plaints and heart failure symptoms according to the NYHA
classification and the completion of a questionnaire were
carried out at the initial visit.
LVEF was evaluated by LV angiography at the point of
EMB [14]. All patients underwent M-mode and 2D echocar-
diography to evaluate LV end diastolic diameter (LVEDD).
Echocardiographic measurements were analysed indepen-
dently in a blinded fashion by two experienced operators.
2.2. Analysis of Surface Markers for Circulating Mesenchymal
Stromal Cells. Peripheral blood mononuclear cells (PBMC)
were isolated using a Ficoll gradient (Histopaque 1077,
Sigma). PBMC were analysed by flow cytometry. First, a
regional gate was defined to exclude debris and platelets
defined by forward/sideward scatter. In order to detect MSC,
CD45−CD34−CD11b− events identified with directly conju-
gated monoclonal antibodies against human CD45, CD34
(both FITC, BD), and CD11b (AF488, BD) were used. A
total of at least 100,000 events in R1 + R2 were counted.
Cells were identified in a forward/sideward scatter (R1).
They were negative for this marker combination (R1 + R2)
and further analysed for the presence of CD105 or CD90
(both APC, BD) and CD73 (PE, BD). However, due to the
rare counts of cells fulfilling these criteria in a number of
patients, further statistical analysis was hindered. Thus, due
to the very close correlation of CD45−CD34−CD11b− with
CD45−CD34−CD11b−CD73+CD90+ (𝑟 = 0.67, 𝑃 < 0.0001)
and with CD45−CD34−CD11b−CD73+CD105+CD90+ (𝑟 =
0.72, 𝑃 < 0.0001), we chose to use CD45−CD34−CD11b−
cells for further analysis. Isotype-identical antibodies served
as controls (Becton Dickinson). Measurements were carried
out in duplicate and the mean value was used for further cal-
culations. All antibodies were tested with cultivated MSC on
passage 6 and with cultivated fibroblasts for their sensitivity
and specificity.
2.3. Transcardiac Gradients of Circulating Mesenchymal Stro-
mal Cells in Inflammatory Cardiomyopathy. As described
previously [15], all patients underwent sampling from the
femoral vein and great cardiac vein for measurement of MSC
and cytokine levels before an EMB specimen was taken.
In patients scheduled for coronary angiography, additional
blood samples were obtained from the aortic root before
injection of the contrast agent. The transcardiac gradients
(TCGs) were expressed in percent changes from values
obtained from either the aortic root or, if not obtainable
there, the femoral vein. A “negative” transcardiac gradient
thusmeans that the number of cells is smaller in the coronary
sinus compared to the aortic root and suggests that cells are
retained in the heart. There were no differences in TCGs
between the 2 methods. In patients, in whom both aortic
root and femoral vein were sampled, comparable values were
obtained from the latter sampling sites.
2.4. Histological and Immunohistological Evaluation of Inflam-
mation in Endomyocardial Biopsies. EMB were obtained
from the right ventricular septum within two days after
angiographic evaluation of LVEF using standard techniques
[16]. Two biopsies were used for the histological evaluation
(paraffin embedded) according to the Dallas criteria [17]
and the immunohistological analysis of inflammation (frozen
sections), respectively [18]. The cut-off value of 9.0 lympho-
cyte function-associated antigen-1 (LFA-1, CD11a) positive
cells/mm2 and 5.5 area fraction (AF)% human leucocyte anti-
gen (HLA) class I and/or 1.2AF%CD54/ICAM-1were used to
differentiate between samples with or without cardiac inflam-
mation. DNA and RNA were extracted simultaneously from
biopsy specimens, and the amplification of viral genomes
was conducted by nested PCR as described [16]. LFA-1, HLA
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class I and CD54/ICAM-1 were detected immunohistochem-
ically as described previously.
2.5. NT-proBNP and SDF-1𝛼 Analysis. Circulating levels of
N-terminal pro-brain natriuretic peptide (NT-proBNP) and
SDF-1𝛼 levels in pre- and postcoronary blood samples were
quantified with respective ELISA kits (R&D, Wiesbaden)
according to the manufacturers’ instructions.
2.6. Real-Time Polymerase Chain Reaction Quantification.
RNA from human biopsies was prepared and reverse
transcribed using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, USA).
Quantitative real-time polymerase chain reaction (PCR)
was used to quantify human SDF-1𝛼 (ABI PRISM 7900
HT Sequence Detection System software version 2.2.2.,
Perkin Elmer) (Eppendorf Mastercycler epgradient realplex,
Hamburg, Germany) expression. Expression levels were
normalized to human ribosomal L32 in all experiments. The
sequences of the primer sets used in this studywere as follows:
human SDF-1𝛼 FOR: 5󸀠-ATGCCCATGCCGATTCTTC-3󸀠
and REV: 5󸀠-GGAGTGTTGAGAATTTTGAGATGCT-3󸀠,
and human ribosomal L32: FOR: 5󸀠-AGGAGAGACACC-
GTCTGAACAAG-3󸀠 and REV: 5󸀠-GAACCAGGATGG-
TCGCTTTC-3󸀠.
2.7. Immunofluorescence Analysis of Mesenchymal Stromal
Cells in Endomyocardial Biopsies. MSC were determined
in LV sections with transversely sectioned cardiomyocytes
immunostained with CD105 and CD90 in the absence of
the markers CD45 and CD34. The ratio of MSC to total
nuclei of cardiomyocytes was calculated. High power fields
(×400, 200𝜇m × 200𝜇m, 8 fields per section) with trans-
versely sectioned cardiomyocytes were recorded to calculate
MSC to cardiomyocyte ratio. Nuclei were stained with 4󸀠,6-
diamino-2-phenylindole (DAPI, dilution, 1 : 200; Sigma). Ki-
67 in nuclei was evaluated with the use of anti-Ki-67 anti-
bodies (Diagnostic Biosystems, Pleasanton, USA). Myocytes
were recognized by means of mouse monoclonal antibodies
against sarcomeric 𝛼-actin (dilution 1 : 50, Sigma). Finally,
sections were mounted and examined under a fluorescence
microscope (Leica). All available fields (40 fields) were
measured.
2.8. Mesenchymal Stromal Cell Isolation. Human adult MSC
were isolated from iliac crest bone marrow aspirates of
healthy donors after their written approval according to
Binger et al. [19]. MSC were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM; Biochrom) supplemented with
10% fetal bovine serum (FBS), 1% penicillin/streptomycin,
1% glutamine, 2% HEPES, and 2 ng/mL of basic fibroblast
growth factor (Tebu-bio, Offenbach, Germany) and plated at
a density of 5 × 103 cells/cm2 before use in the respective
experiments. Cultivated MSC were triple negative for the
markers CD45, CD34, and CD11b but stained positively for
the markers CD73, CD29, CD105, CD106, CD90, and CD44,
thereby confirming sensitivity and specificity of our antibody
sets (Figure 1(a)).
2.9. Migration Assay. HL-1 cells were plated in a 6-well
plate at a density of 300,000 cells/well in Claycomb medium
(Sigma) supplemented with 10% FBS, 1% penicillin/strep-
tomycin, 100 𝜇M norepinephrine (Sigma), and 2mM L-
glutamine (Biochrom AG, Berlin, Germany). After twenty-
four hours, cells were washed and cultured for an additional
24 h in serum starvation medium (DMEM 11966 medium
(Invitrogen, Carlsbad) supplemented with 0.1% FBS, 5mM
glucose, and 1% penicillin/streptomycin) in the presence or
absence of 10 ng/mL of recombinant TNF-𝛼 (R&D Systems).
Then, the supernatant (conditioned medium) was collected
and stored at −20∘C until further use.
Conditioned medium of unstimulated or TNF-𝛼-
stimulated HL- 1 cells, in the presence or absence of 5𝜇g/mL
of anti-SDF-𝛼 (R&D Systems) and corresponding mouse
isotype control (Santa Cruz Biotechn Inc., Cambridge,
USA) or 2.5 𝜇g/mL of anti-MCP-1 (R&D Systems) and
corresponding rat isotype control (Santa Cruz Biotechn
Inc.) was added to the bottom chamber of the chemotaxis
chamber (ChemoTX, 8 𝜇M pore, Neuroprobe, Gaithersburg,
MD, USA). A total of 3 × 104 MSC, resuspended in DMEM
(Sigma), containing 0.01% FBS, 2mM L-glutamine, 20mM
HEPES (Invitrogen), and 1% penicillin/streptomycin, were
plated in the upper chemotaxis chamber. After 24 hours of
incubation at 37∘C, the lower side of the filter was washed
with PBS and fixed in 50% acetone/50% methanol. Next,
cells were stained with crystal violet (Sigma) and quantified
by spectophotometric measurement at 560 nm. Data are
depicted as the migration of MSC versus conditioned
medium of unstimulated HL-1 cells (basal) set as 1 and
represented as mean ± SEM of 𝑛 = 4 wells/condition.
In the case of migration assays of MSC towards serum
of patients, 1% of patient serum was added to the bottom
chamber of the chemotaxis chamber (ChemoTX, 8𝜇M pore,
Neuroprobe, Gaithersburg, MD, USA) in the presence or
absence of anti-SDF-𝛼 and corresponding mouse isotype
control. A total of 3 × 104 MSC, resuspended in DMEM
(Sigma), containing 0.01% FBS, 2mM L-glutamine, 20mM
HEPES (Invitrogen), and 1% penicillin/streptomycin, was
plated in the upper chemotaxis chamber. After 24 hours of
incubation at 37∘C, the lower side of the filter was washed
with PBS and fixed in 50% acetone/50% methanol. A MSC
standard was plated out on a separate membrane and after
2 hours, the membrane was fixed in 50% acetone/50%
methanol. Next, cells were stainedwith crystal violet (Sigma).
The optical density of the wells on the filter was analyzed
via Image J and the corresponding cell number per well
calculated. Data are depicted as migrated cells.
2.10. Statistical Analysis. Continuous variables were tested
for normal distribution with the Kolmogorov-Smirnov test.
Comparisons between the two groups were analysed by 𝑡-
test (two-sided) for normally distributed variables. Data are
expressed as mean ± SD, unless otherwise stated. Nonnor-
mally distributed continuous variables (MSC, hs-CRP, LFA-
1, NT-proBNP) were compared by the Mann-Whitney 𝑈
test and are presented as median and interquartile range
[IQR]. Comparison of categorical variables was generated by













































































































Figure 1: Flow cytometry analysis strategy and quantification of transcardiac gradients of circulating MSC in CMi. (a) Cultivated MSC (bar
indicates 200𝜇m) isolated from bone marrow were stained with directly FITC-conjugated monoclonal antibodies against human CD45 and
CD34, and anti-CD11b directly conjugated to AF488 (all from BD). After setting a morphological gate defined by forward/side scatter (FSC
and SSC, R1), CD45−CD34−CD11b− cells (R2) defined as belonging to both R1 and R2 (first row) were stained with CD73-PE, CD106-APC,
CD90-APC, CD29-APC, CD105-APC, or CD44-APC (second row). (b) Measurement of circulating MSC in patients with CMi. MNCs were
isolated from peripheral blood using a Ficoll gradient. Circulating MSC were analysed by flow cytometry. First, a regional gate was defined
to exclude debris and platelets defined by forward/side scatter (FSC and SSC, R1). The events in R1 are then displayed on a CD45CD34CD11b
versus SSC dot plot and a second gate (R2) is produced to include the cluster of CD45−CD34−CD11b− cells. The right margin was fixed for
all patients. A total of at least 100,000 events in R1 and R2 were counted. (c) Quantification of the number of circulating MSC sampled from
the aortic root and simultaneously from the coronary sinus in patients with cardiac inflammation (box plots are given as median and IQR;
whiskers represent 95%CI).The lines between the boxes represent numbers of CD45−CD34−CD11b−/100MNC sampled from either the aorta
or coronary sinus of the same individual.
the Pearson 𝜒2 test. Multivariate linear regression analysis
and nonparametric bivariate correlation (Spearman rank
correlation coefficient) were used to correlate counts of
circulating MSC or MSC in EMB with cardiac inflammation,
NTproBNP, SDF-1𝛼, MCP-1, and LVEF. To identify inde-
pendent determinants of MSC counts, a multivariate linear
regression analysis for the abovementioned parameters was
performed.
Statistical significance was assumed, if a null hypothesis
could be rejected at 𝑃 ≤ 0.05. All statistical analysis was
performed with SPSS 21 (SPSS Inc.).
3. Results
3.1. Patient Characteristics. The baseline characteristics of
the 29 subjects are summarised in Table 1. Twenty-three
Mediators of Inflammation 5
Table 1: Patients’ baseline characteristics.
Parameter Total population No cardiac inflammation Cardiac inflammation Significance
𝑛 29 6 23
Age (years) 48 ± 16 48 ± 15 51 ± 14 n.s.
Male gender 16 (55%) 4 (67%) 12 (52%) n.s.
NYHA class 4/14/8/2 1/4/1/0 3/10/7/2 n.s.
(I/II/III/IV), in % (14/48/27/7) (17/67/17/0) (13/44/30/9)
Duration of symptoms (month) 3.6 ± 2.4 3.5 ± 3.2 3.7 ± 2.3 n.s.
Cardiac risk factors
Smoking 8 (28%) 3 (50%) 4 (17%) n.s.
Diabetes mellitus 1 (3%) 0 1 (4%) n.s.
Hypercholesterinaemia 11 (38%) 1 (17%) 10 (44%) n.s
Arterial hypertension 16 (55%) 4 (67%) 12 (52%) n.s.
Medication
ACE-inhibitors/AT1-blocker 16 (55%) 4 (67%) 10 (44%) n.s.
𝛽-blocker 19 (66%) 3 (50%) 13 (57%) n.s.
Statins 6 (21%) 1 (17%) 4 (17%) n.s.
Haemodynamic and echocardiographic measurements
LVEF (%) 52 ± 16 58 ± 22 49 ± 15 0.16
LVEDD (mm) 55.3 ± 8.1 51.6 ± 6.13 59.78 ± 11 0.04
Laboratory parameters
Leukocyte count (/nl) 7.3 ± 2.3 6.4 ± 1.6 7.3 ± 1.9 n.s.
Hs-CRP (mg/dl) 1.9 ± 5.2 1.2 ± 1.8 2.1 ± 6.1 n.s.
NT-proBNP (pg/ml) 949 ± 1901 890 ± 949 1089 ± 2097 n.s.
Endomyocardial biopsy
CD3 (/mm2) 18.8 ± 55.6 4 ± 2 23 ± 61 0.04
LFA-1 (/mm2) 27.5 ± 56.6 7 ± 2 33 ± 63 n.a.
HLA (AF%) 8.9 ± 5.0 7 ± 2 9 ± 6 n.s.
NYHA: dyspnoea according to the New York Heart Association; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter; hs-
CRP: high sensitivity C-reactive protein; CD3: T-lymphocytes; LFA: lymphocyte function-associated antigen-1, CD11a; HLA: human leukocyte antigen; AF:
area fraction. Significant 𝑃 values are given for subgroup analyses.
(79%) patients showed an increased cardiac inflammation
response in EMB. Patients with cardiac inflammation had
a similar LVEF and a slightly increased LVEDD compared
to patients without inflammation. Except for these, no dif-
ferences regarding concomitant medication, age, gender, or
duration of symptoms were apparent.
3.2. Circulating Mesenchymal Stromal Cells in Humans.
Circulating MSC defined by the absence for the mark-
ers CD45, CD34, and CD11b and by staining positive
for CD73, CD105, and CD90 counted for 0.010 [0.0025–
0.048]%/PMNCwith similar counts in patients with or with-
out cardiac inflammation. When considering only the nega-
tive marker combination (Figure 1(b)), MSC comprised 0.62
[0.38–1.15]%/PBMCs, again with similar counts in patients
with or without cardiac inflammation (0.52 [0.29–1.0] versus
0.76 [0.38–1.34]%/PBMC). No correlation was seen between
circulating MSC and cardiac inflammation, LVEF, leukocyte
count, or hs-CRP, indicating that inflammation per se has no
direct effect on circulating MSC counts.
3.3. Transcardiac Gradients of Circulating Mesenchymal Stro-
mal Cells in Patients. Transcardiac gradients of circulating
MSC were measured after simultaneous sampling of the
aorta and the coronary sinus in all patients. As illustrated
in Figure 2(a), patients with cardiac inflammation (𝑛 = 23)
had a significant 29.9% reduction of MSC after transcardiac
passage (𝑃 < 0.01, Figure 1(c)), in contrast (𝑃 < 0.001) to
patients without cardiac inflammation (𝑛 = 6). Since SDF-1𝛼
is a potent chemoattractant for MSC [12], SDF-1𝛼 mRNA
was quantified in EMB. There was a negative transcardiac
gradient of MSC in patients with SDF-1𝛼 mRNA in their
EMB > median (>2.7-fold compared to GAPDH; 𝑃 < 0.05,
Figure 2(b)). Cardiac inflammation and SDF-1𝛼mRNA levels
were inversely correlated with the transcardiac gradients of
circulating MSC (cardiac inflammation: 𝑟 = −0.39, 𝑃 < 0.05,
Figure 2(c)). Furthermore, there was a negative correlation
between the transcardiac gradients of circulating MSC and
NT-proBNP (𝑟 = −0.46, 𝑃 < 0.05, data not shown), but
not with LVEF. By multivariate analysis, including LVEF,
NT-proBNP, cardiac inflammation (LFA-macrophages), and
cardiac SDF-1𝛼 mRNA, cardiac inflammation remained the
only significant independent predictor for declined numbers
of circulating MSC after transcardiac passage (𝑃 < 0.001
for trend (ANOVA), 𝐵 = −0.73, 𝑃 < 0.005). Interestingly,
systemic SDF-1𝛼 levels were significantly induced in patients







































































































































Figure 2: Transcardiac gradients of circulating MSC and Stromal derived factor-1𝛼 (SDF-1𝛼) related to cardiac inflammation and expression
of SDF-1 mRNA. (a) Quantitative analysis of transcardiac gradients of MSC in patients without (𝑛 = 6) and with (𝑛 = 23) cardiac
inflammation, as defined by the number of LFA-positive cells, is given as median and IQR; whiskers represent 95% CI. (b) Transcardiac
gradient of MSC after dichotomisation with respect to SDF-1𝛼mRNA in their EMB (cut-off: median, box plots are given as median and IQR;
whiskers represent 95% CI). (c) Correlation between transcardiac gradients of MSC and cardiac inflammation. (d) Postcoronary SDF-1𝛼
levels (pg/mL) in patients without and with cardiac inflammation; bar graphs represent the mean ± SEM.
with cardiac inflammation compared to patients without
cardiac inflammation (Figure 2(d)) with no further increase
after transcardiac passage in both, patients with or without
cardiac inflammation. Furthermore, MSC migration was
only tendentiously (𝑃 = 0.1) more pronounced versus post-
coronary or venous serum of patients with cardiac inflamma-
tion compared to serum of patients without inflammation
(data not shown). However, no SDF-1𝛼-dependency could
be detected, as shown in a blocking experiment (data not
shown).
3.4. Mesenchymal Stromal Cells in Human Endomyocardial
Biopsies. As shown in the representative image, MSC can
be identified in the myocardium (Figure 3(a)). Figure 3(b)
illustrates that patients with cardiac inflammation showed
a trend towards increased numbers of MSC (CD45−CD34−
CD90+CD105+, 0.80 ± 0.67 versus 1.89 ± 1.03/100mm2,
𝑃 = 0.058) in their EMB compared to patients without
inflammation and showed a strong correlation betweenMSC
and cardiac inflammation (𝑟 = 0.64, 𝑃 = 0.0001, not shown).
Related to the number of cardiomyocytes, there were around
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100𝜇m×400
Overlay actin, DAPI, CD105, CD45, ki67




Figure 3: Immunostaining and quantification of cardiac MSC related to cardiac inflammation and expression of SDF-1𝛼 mRNA. (a)
Representative image of immunofluorescence of MSC in EMB. Serial sections were stained with (A) an overlay of 𝛼-sarcomeric actin (red),
nuclear counterstained (DAPI, blue), anti-CD105 and anti-CD90 (red, and B), and anti-CD45 (green, and C) as a lymphocytes marker (the
arrow image (A) highlights the MSC). (b) Quantitative analysis of CD45−CD34−CD105+CD90+-MSC in EMB of patients without (𝑛 = 6)
and with (𝑛 = 23) cardiac inflammation, as defined by the number of LFA-positive cells (box plots are given as median and IQR; whiskers
represent 95% CI). (c) Quantitative analysis of CD45−CD34−CD105+CD90+-MSC in EMB after dichotomisation with respect to SDF-1𝛼
mRNA expression in their EMB (cut-off: median, box plots are given for median and IQR; whiskers represent 95% CI). (d) Correlation
between the transcardiac gradient of circulating MSC and MSC in EMB. (e) Representative image of immunofluorescence of MSC and
proliferation in EMB.The same serial sections as indicated above (3(a)) were stained with (A) anti-Ki67 (yellow) for proliferation, (B) overlay
of CD105 (red), anti-CD45 (green), and Ki67 (yellow), and (C) overlay of 𝛼-sarcomeric actin (red), nuclei (DAPI, blue), CD105 (red), anti-
CD45 (green), and Ki67 (yellow).
2MSC/5000 cardiomyocytes. Time to diagnosis was identical
in both subgroups (3.7 ± 2.3 versus 3.5 ± 3.2month, 𝑃 = 0.7).
In agreement with the key role of SDF-1𝛼 in the retention of
MSC, SDF-1𝛼mRNA levels in EMB correlated with numbers
of MSC in EMB (𝑟 = 0.64, 𝑃 = 0.001, not show). Indeed, as
shown in Figure 3(c), the numbers of MSC were significantly
higher (𝑃 < 0.001) in the group of patients with SDF-
1𝛼 mRNA expression above the median. By multivariate
analysis, including LVEF, NT-proBNP, cardiac inflammation,
and SDF-1𝛼, SDF-1𝛼was the strongest predictor for increased
numbers ofMSC in EMB (𝑃 < 0.001 for trend (ANOVA),𝐵 =
0.91, 𝑃 < 0.005). These findings thus support a pivotal role of
SDF-1𝛼 in the cardiac retention ofMSC in the setting of CMi.
3.5. Mesenchymal Stromal Cells in Endomyocardial Biopsies
and Transcardiac Gradients of Circulating Mesenchymal Stro-
mal Cells. As shown in Figure 3(d), there was a significant
inverse correlation between the number of MSC in EMB
and transcardiac gradients of circulating MSC (𝑟 = −0.47,
𝑃 < 0.05). Highest numbers of MSC in the EMB with
the highest transcardiac gradients of circulating MSC are a
first hint that MSC home to the myocardium. To further
investigate whether the increased numbers of MSC in EMB
were due to a potential replication of these cells in the heart,
we analyzed Ki67 as nuclear marker for proliferation inMSC.
As shown in the representative pictures in Figure 3(e), there
was no costaining of Ki67 inMSC in EMB detectable, further
supporting the constant migration of MSC. Due to the very
rare number of Ki67+ cells, no further quantitative analysis
could be performed.
3.6. SDF-1𝛼- and MCP-1-Dependent Migration of Mesenchy-
mal Stromal Cells In Vitro. To assess the cardiac homing of
circulating MSC towards inflamed hearts and to investigate
which chemokines trigger the cardiac homing in patients
with CMi, the migratory potential of MSC was determined
towards conditionedmedium of TNF-𝛼 stimulated HL-1 car-
diomyocytes, to mimic the inflamed condition, in the pres-
ence or absence of a SDF-1𝛼- or MCP-1 antibody. Medium
of TNF-𝛼-stimulatedmurine HL-1 cardiomyocytes increased
the migration of MSC by 10% (𝑃 < 0.005) compared to basal
conditioned medium of HL-1. This effect was impaired in
the presence of an SDF-1𝛼-antibody or in the presence of an
MCP-1 antibody, but not in the presence of their respective
IgG isotype controls (Figure 4).
4. Discussion
The salient findings of this study are that endogenous MSC
migrate into the heart of patients with virus negative CMi































































Figure 4: SDF-1𝛼- and MCP-1-dependent migration of MSC
in vitro. Migration of MSC (in arbitrary units) towards basal
conditioned medium of HL-1 cardiomyocytes and that of HL-1
cardiomyocytes stimulated with TNF-𝛼, in the presence or absence
of a SDF-𝛼-antibody, MCP-1-antibody, or IgG-antibody. Columns
represent mean ± SEM with 𝑛 = 4/group.
depending on the grade of inflammation and that the number
of retained cardiac MSC is related to the expression of SDF-
1𝛼. The increased number of MSC in the myocardium of
patients with CMi is, at least in part, due to a constant
recruitment of these cells.
Several studies in patients with heart failure have demon-
strated the presence of humoral and cellular immunity
activation, thus suggesting a possible relationship between
dilated cardiomyopathy and inflammation [14]. In heart
failure patients, inflammation is a strong predictor of negative
outcome [2]. The nature of MSC with their immunomod-
ulatory potential has moved these cells into the focus of
novel therapeutic strategies for the treatment of heart failure.
Recent data in experimentalmodels of CMi [8, 13] underscore
the potential of i.v. application of MSC to treat CMi. We
and others have shown reduced cardiomyocytes injury in the
setting of virus-induced acute myocarditis through paracrine
and immunomodulatory effects ofMSC [8, 13, 20], indicating
beneficial effects of MSC in CMi. Most likely paracrine
actions ormodulation of regulatory immune cells account for
the action of this admittedly small amount of MSC homed to
the heart. This is in line with other findings from other pro-
genitor cells present in small numbers in the heart exerting
their effect on cardiac regeneration in the setting of ischaemia
[21], advanced cardiomyopathies [20], and inflammation
[22]. Given the significance of the cardiosplenic axis in the
pathogenesis of CMi [13, 23] and heart failure [24], an impor-
tant contribution of targeting of MSC to the spleen and sub-
sequent immunomodulatory effects should be considered in
the final cardioprotective effects of MSC after i.v. application.
At present, no clinical studies in patients with CMi have
yet been performed involving i.v. administration of MSC and
a direct proof that these multipotent cells play a physiological
role in human CMi is lacking.
We therefore investigated whether endogenous circulat-
ing MCS migrate and home into the myocardium in CMi
patients. In our study, there was a significant transcardiac
reduction of circulatingMSC in patients with cardiac inflam-
mation. However, cardiac inflammation per se does not
determinate numbers of cardiac MSC. The association of
reduction of circulatingMSCwith increase of cardiacMSC is
a hint towards homing of MSC to the site of injury in CMi.
Here, we are in line with other studies [20] demonstrating
that MSC selectively home to sites of injury, irrespective of
the type of tissue.
Among different mechanisms leading to a continuous
recruitment of MSC into the heart of patients with CMi,
SDF-1𝛼 [25, 26] is known to be crucial for local retention
of stem cells. Our findings are consistent with those results:
the homing factor SDF-1𝛼 had the strongest association with
numbers cardiac of MSC, as marker for cardiac retention,
in our patients with CMi, whereas inflammation was the
strongest determinant for continuous declined numbers of
circulating MSC after transcardiac passage as indicator for
migration. This could also be confirmed in vitro where
SDF-1𝛼 was not shown as main contributor to migration.
Furthermore, we did not see any proliferation of cardiac
MSC, which supports our hypothesis that MSC are rather
constantly recruited.
In brief, this study underscores the importance of the
SDF-1𝛼/CXCR4 axis in the cardiac homing of MSC by
CMi. This finding as well as the observation that CXCR4
expression is decreased upon cell culture expansion [27]
stresses the relevance to induce CXCR4 expression in MSC
before injection. Due to the clinical nature of this study,
further conclusions as to the major sources and orchestration
of chemokines involved in MSC homing and retention and
further mechanistic insights are precluded.
Furthermore, it has to be acknowledged that despite
the well-documented cardioprotective effects of MSC in
experimental models of CMi [8, 13], further studies will have
to address the fate and function, repair ofCMi or contribution
to the pathogenesis of CMi, of endogenous cardiac MSC in
humans.
5. Conclusion
We provide evidence that endogenous circulating MSC are
constantly recruited into the myocardium of patients with
CMi. It will be the aim of future studies to analyse the







LVEF: Left ventricular ejection fraction
MSC: Mesenchymal stromal cell
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MNC: Mononuclear cell
MCP-1: Monocyte chemoattractant protein-1
NT-proBNP: N-Terminal pro-brain natriuretic peptide
PBMCs: Peripheral blood mononuclear cells
PCR: Polymerase chain reaction
SDF-1𝛼: Stromal derived factor-1𝛼
TCG: Transcardiac gradient.
Conflict of Interests
The authors declare that they have no conflict of interests.
Authors’ Contribution
Caroline Schmidt-Luckec and Felicitas Escher contributed
equally to this work.
Acknowledgments
This study was supported by the Deutsche Forschungsge-
sellschaft (DFG; SFB/TR-19; B5; B6; Z1; Z3) and a grant
from the Berlin-Brandenburg Center for Regenerative Ther-
apies (BCRT). Carsten Tscho¨pe, Felicitas Escher, and Sophie
Van Linthout are supported by the Deutsches Zentrum fu¨r
Herz-Kreislauf-Forschung (German Centre for Cardiovas-
cular Research). The authors are grateful to Jung Peng,
Marzena Sosnowski, Karen Bo¨hme, Annika Koschel, and
Olga Khokhlova for excellent expert assistance.
References
[1] L. T. Cooper Jr., “Myocarditis,” The New England Journal of
Medicine, vol. 360, no. 15, pp. 1526–1538, 2009.
[2] I. Kindermann, M. Kindermann, R. Kandolf et al., “Predictors
of outcome in patients with suspectedmyocarditis,”Circulation,
vol. 118, no. 6, pp. 639–648, 2008.
[3] S. Heymans, E. Hirsch, S. D. Anker et al., “Inflammation as a
therapeutic target in heart failure? A scientific statement from
the Translational Research Committee of the Heart Failure
Association of the European Society of Cardiology,” European
Journal of Heart Failure, vol. 11, no. 2, pp. 119–129, 2009.
[4] P. P. Liu and J. W. Mason, “Advances in the understanding of
myocarditis,” Circulation, vol. 104, no. 9, pp. 1076–1082, 2001.
[5] M. Mirotsou, T. M. Jayawardena, J. Schmeckpeper, M. Gnecchi,
and V. J. Dzau, “Paracrine mechanisms of stem cell reparative
and regenerative actions in the heart,” Journal of Molecular and
Cellular Cardiology, vol. 50, no. 2, pp. 280–289, 2011.
[6] M. Gnecchi, Z. Zhang, A. Ni, and V. J. Dzau, “Paracrine mech-
anisms in adult stem cell signaling and therapy,” Circulation
Research, vol. 103, no. 11, pp. 1204–1219, 2008.
[7] K. E. Hatzistergos, H. Quevedo, B. N. Oskouei et al., “Bone
marrow mesenchymal stem cells stimulate cardiac stem cell
proliferation and differentiation,” Circulation Research, vol. 107,
no. 7, pp. 913–922, 2010.
[8] S. van Linthout, K. Savvatis, K. Miteva et al., “Mesenchymal
stem cells improve murine acute coxsackievirus B3-induced
myocarditis,” European Heart Journal, vol. 32, no. 17, pp. 2168–
2178, 2011.
[9] S.-H. Yang, M.-J. Park, I.-H. Yoon et al., “Soluble mediators
from mesenchymal stem cells suppress T cell proliferation by
inducing IL-10,” Experimental and Molecular Medicine, vol. 41,
no. 5, pp. 315–324, 2009.
[10] K. Le Blanc, L. Tammik, B. Sundberg, S. E. Haynesworth, andO.
Ringde´n, “Mesenchymal stem cells inhibit and stimulate mixed
lymphocyte cultures andmitogenic responses independently of
the major histocompatibility complex,” Scandinavian Journal of
Immunology, vol. 57, no. 1, pp. 11–20, 2003.
[11] A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze,
and W. E. Fibbe, “Mesenchymal stem cells inhibit generation
and function of both CD34+-derived and monocyte-derived
dendritic cells,” Journal of Immunology, vol. 177, no. 4, pp. 2080–
2087, 2006.
[12] M. Honczarenko, Y. Le, M. Swierkowski, I. Ghiran, A. M.
Glodek, and L. E. Silberstein, “Human bone marrow stromal
cells express a distinct set of biologically functional chemokine
receptors,” Stem Cells, vol. 24, no. 4, pp. 1030–1041, 2006.
[13] K. Savvatis, S. van Linthout, K. Miteva et al., “Mesenchymal
stromal cells but not cardiac fibroblasts exert beneficial systemic
immunomodulatory effects in experimental myocarditis,” PLoS
ONE, vol. 7, no. 7, Article ID e41047, 2012.
[14] L. T. Cooper, K. L. Baughman, A. M. Feldman et al., “The role
of endomyocardial biopsy in themanagement of cardiovascular
disease: a scientific statement from the American Heart Associ-
ation, the American College of Cardiology, and the European
Society of Cardiology,” Circulation, vol. 116, no. 19, pp. 2216–
2233, 2007.
[15] C. Schmidt-Lucke, A. Aicher, P. Romagnani et al., “Specific
recruitment ofCD4+CD25++ regulatoryT cells into the allograft
in heart transplant recipients,”American Journal of Physiology—
Heart and Circulatory Physiology, vol. 292, no. 5, pp. H2425–
H2431, 2007.
[16] F. Escher, R. Vetter, U. Ku¨hl, D. Westermann, H.-P. Schultheiss,
and C. Tscho¨pe, “Fractalkine in human inflammatory car-
diomyopathy,” Heart, vol. 97, no. 9, pp. 733–739, 2011.
[17] H. T.Aretz, “Myocarditis: theDallas criteria,”HumanPathology,
vol. 18, no. 6, pp. 619–624, 1987.
[18] U. Kuhl, M. Noutsias, B. Seeberg, and H.-P. Schultheiss,
“Immunohistological evidence for a chronic intramyocardial
inflammatory process in dilated cardiomyopathy,” Heart, vol.
75, no. 3, pp. 295–300, 1996.
[19] T. Binger, S. Stich, K. Andreas et al., “Migration potential
and gene expression profile of human mesenchymal stem cells
induced by CCL25,” Experimental Cell Research, vol. 315, no. 8,
pp. 1468–1479, 2009.
[20] S. Ohnishi, B. Yanagawa, K. Tanaka et al., “Transplantation
of mesenchymal stem cells attenuates myocardial injury and
dysfunction in a rat model of acute myocarditis,” Journal of
Molecular and Cellular Cardiology, vol. 42, no. 1, pp. 88–97, 2007.
[21] C. Bearzi, A. Leri, F. lo Monaco et al., “Identification of a coro-
nary vascular progenitor cell in the human heart,”Proceedings of
the National Academy of Sciences of the United States of America,
vol. 106, no. 37, pp. 15885–15890, 2009.
[22] A. J. Boyle, S. P. Schulman, and J. M. Hare, “Stem cell therapy
for cardiac repair: ready for the next step,” Circulation, vol. 114,
no. 4, pp. 339–352, 2006.
[23] K. Miteva, S. van Linthout, H.-D. Volk, and C. Tscho¨pe,
“Immunomodulatory effects of mesenchymal stromal cells
revisited in the context of inflammatory cardiomyopathy,” Stem
Cells International, vol. 2013, Article ID 353097, 16 pages, 2013.
[24] M. A. Ismahil, T. Hamid, S. S. Bansal, B. Patel, J. R. Kingery, and
S. D. Prabhu, “Remodeling of the mononuclear phagocyte net-
work underlies chronic inflammation and disease progression
Mediators of Inflammation 11
in heart failure: critical importance of the cardiosplenic axis,”
Circulation Research, vol. 114, no. 2, pp. 266–282, 2014.
[25] A. Peled, I. Petit, O. Kollet et al., “Dependence of human
stem cell engraftment and repopulation of NOD/SCIDmice on
CXCR4,” Science, vol. 283, no. 5403, pp. 845–848, 1999.
[26] J. D. Abbott, Y. Huang, D. Liu, R. Hickey, D. S. Krause, and F.
J. Giordano, “Stromal cell-derived factor-1𝛼 plays a critical role
in stem cell recruitment to the heart after myocardial infarction
but is not sufficient to induce homing in the absence of injury,”
Circulation, vol. 110, no. 21, pp. 3300–3305, 2004.
[27] L. A. Marquez-Curtis and A. Janowska-Wieczorek, “Enhancing
the migration ability of mesenchymal stromal cells by targeting
the SDF-1/CXCR4 axis,” BioMed Research International, vol.
2013, Article ID 561098, 15 pages, 2013.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
